Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

Chemotherapy-Induced Nausea and Vomiting: 5-HT₃ Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Quality of Life Identifies High-Risk Groups in Advanced Rectal Cancer Patients.

Healthcare (Basel, Switzerland)·2025

Same author

Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO-007 Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2025

Same author

Chemoradiation-Altered Micromilieu of Glioblastoma Cells Particularly Impacts M1-like Macrophage Activation.

International journal of molecular sciences·2025

Same author

Comparison of dose calculation approaches and clinical dose-response in image-guided head&neck brachytherapy of the oral cavity.

Clinical and translational radiation oncology·2025

Same author

Prognostic Significance of Macrophage Phenotypes in Peri-Tumoral Normal Tissue of Early-Stage Breast Cancer.

Cells·2025

Same author

A Systematic Review and Meta-analysis on Perioperative Stenting/Dwell Time and Postoperative Outcomes in Patients Undergoing Radical Cystectomy and Urinary Diversion for Bladder Cancer.

European urology focus·2025

Same journal

Proton therapy in the clinic.

Frontiers of radiation therapy and oncology·2011

Same journal

Proton therapy: clinical gains through current and future treatment programs.

Frontiers of radiation therapy and oncology·2011

Same journal

Stereotactic body radiotherapy for prostate cancer: current results of a phase II trial.

Frontiers of radiation therapy and oncology·2011

Same journal

Stereotactic body radiation therapy for gastrointestinal malignancies.

Frontiers of radiation therapy and oncology·2011

Same journal

Stereotactic body radiation therapy for thoracic cancers: recommendations for patient selection, setup and therapy.

Frontiers of radiation therapy and oncology·2011

Same journal

Stereotactic body radiation therapy: normal tissue and tumor control effects with large dose per fraction.

Frontiers of radiation therapy and oncology·2011

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 18, 2026

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Published on: January 17, 2025

Stage III: definitive chemoradiotherapy.

Rainer Fietkau, Sabine Semrau

Frontiers of Radiation Therapy and Oncology

|December 4, 2009

Summary

This summary is machine-generated.

Concurrent chemoradiotherapy is the standard for inoperable stage III non-small cell lung cancer. Adding induction or adjuvant chemotherapy does not improve outcomes and should be reserved for clinical trials.

More Related Videos

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma

Published on: February 13, 2026

Related Experiment Videos

Last Updated: Jun 18, 2026

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Complete Laparoscopic Radical Resection of Perihilar Cholangiocarcinoma Type IIIb

Published on: January 17, 2025

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma

Intraoperative Strategy under Complex Vascular Adhesion for Laparoscopic Radical Resection of Bismuth-Corlette Type IIIb Perihilar Cholangiocarcinoma

Published on: February 13, 2026

Area of Science:

Oncology
Radiotherapy
Medical Oncology

Background:

Concurrent chemoradiotherapy is the standard of care for inoperable stage III non-small cell lung cancer.
Conventionally fractionated radiotherapy up to 60-66 Gy is effective.
Cisplatin-based or carboplatin chemotherapy regimens are recommended.

Purpose of the Study:

To outline the current standard treatment for stage III inoperable non-small cell lung cancer.
To discuss chemotherapy options and the role of induction/adjuvant therapies.
To address considerations for elderly patients and those with comorbidities.

Main Methods:

Review of current treatment guidelines and clinical trial evidence.
Analysis of chemotherapy regimens (cisplatin-based, carboplatin) and potential combinations (etoposide, vinorelbine, paclitaxel, gemcitabine).
Evaluation of prognostic factors including age and comorbidities.

Main Results:

Concurrent chemoradiotherapy with conventionally fractionated doses is effective.
No evidence supports induction or adjuvant chemotherapy in randomized trials.
Elderly patients and those with comorbidities may experience more side effects, requiring intensive supportive care.

Conclusions:

Concurrent chemoradiotherapy is the established treatment for this patient group.
Induction or adjuvant chemotherapy should not be used outside clinical trials.
While age is not an absolute contraindication, reduced cardiopulmonary function may impact prognosis.